Medicare's Part B Reform Proposal May Be Gaining Momentum; Congress Not Hearing Strong Protests
Executive Summary
Muted stakeholder reactions may reflect Trump Administration efforts to address physician concerns in its Medicare Part B drug payment reform.
You may also be interested in...
Can Medicare International Price Index Model Avoid Part B Demo Pitfalls?
Mandatory nature of demonstration might hamper progress of new model for changing Medicare Part B drug reimbursement, as it did when Obama Administration tried it.
Medicare's Foreign Price Bench-marking Will Only Hurt Bad Negotiators, HHS's Azar Argues
President Trump touts CMS proposal that would peg Part B prices to an international index in the hopes of lowering US costs; industry calls it foreign price controls and warns it will hinder access.
CMS Cancels Part B Demo Before HHS Secretary-Designate Price Does
President-elect Trump’s selection for HHS secretary, Rep. Tom Price, R-Ga., has been an outspoken critic of the proposed Medicare Part B drug demonstration project.